Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on October 6, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 815,000 shares for a total of 550 million [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for 23.98 million [2]. - Mengniu Dairy (02319) repurchased 1 million shares for 14.41 million [2]. - Antonoil Oilfield Services (03337) repurchased 8.4 million shares for 9.99 million [2]. - Cloud Factory (N23027) repurchased 1.896 million shares for 9.17 million [2]. Group 2: Cumulative Buyback Data - Tencent Holdings has a cumulative buyback of 68.257 million shares, representing 0.743% of its total share capital [2]. - Hang Seng Bank has a cumulative buyback of 9.13 million shares, representing 0.485% of its total share capital [2]. - Mengniu Dairy has a cumulative buyback of 15.516 million shares, representing 0.397% of its total share capital [2]. - Antonoil Oilfield Services has a cumulative buyback of 10.5 million shares, representing 0.350% of its total share capital [2]. - Cloud Factory has a cumulative buyback of 10.24 million shares, representing 2.226% of its total share capital [2].

石四药集团(02005)发布公告，于2025年10月6日斥资869.89万港元回购300万股股份。 ...

智通财经APP讯，石四药集团(02005)发布公告，于2025年10月6日斥资869.89万港元回购300万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 石四藥集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月底法定/ ...

Core Insights - The latest shareholder equity disclosures for companies including Stone Four Pharmaceutical Group, Cornerstone Pharmaceuticals-B, and Huilyang Technology were made on September 26, 2025 [1] Group 1: Stone Four Pharmaceutical Group (02005) - China Pharmaceutical increased its holdings from 884 million shares to 885 million shares, representing a holding percentage change from 29.95% to 29.99% [2] - Qu Jiguang raised his stake from 1.204 billion shares to 1.205 billion shares, with a holding percentage change from 40.78% to 40.82% [2] Group 2: Cornerstone Pharmaceuticals-B (02616) - Yang Jianxin increased his holdings from 70.0927 million shares to 70.2427 million shares, with a holding percentage change from 4.75% to 4.76% [2] Group 3: Huilyang Technology (01860) - Song Xiaofei reduced his holdings from 2.1924 million shares to 2.0004 million shares, with a holding percentage change from 0.14% to 0.13% [2]

格隆汇9月26日丨根据联交所最新权益披露资料显示，2025年9月25日，石四药集团(02005.HK)获执行董事兼主席兼行政总裁曲继广在场内以每股均2.9659港 元增持120万股，涉资约355.91万港元。 增持后，曲继广最新持股数目为1,204,792,000股，持股比例由40.78%上升至40.82%。 | 股份代號: | 02005 | | --- | --- | | 上市法國名稱: | 石四藥集團有限公司 | | 日期 (日 / 月 / 年): | 26/08/2025 - 26/09 | | 200 - 12 - | | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | | 大家网 三亚 | | | 請參閱上述 * 註 有投票權股 期 (日 / 月 / 份權益 | | | | | | | | · | | | CS20250925E00195 | China Pharmaceutical | 1710(L ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 华新水泥(06655) | 李叶青 | 好仓 | 108.39 万股 | 113.01 万股 | 0.15%(最新) | | | | | | | 0.15%(前次) | | 腾盛博药 | Hong Zhi | 好仓 | 4157.19 万股 | 4154.75 万股 | 5.67%(最新) | | B(02137) | | | | | 5.67%(前次) | | 石四药集团 | 曲继广 | 好仓 | 12.03 亿股 | 12.04 亿股 | 40.78%(最新) | | (02005) | | | | | 40.75%(前次) | | 石四药集团 | China Pharmaceutical | 好仓 | 8.83 亿股 | 8.84 亿股 | 29.95%(最新) | | (02005) | Company Limited | | | | 29.91%(前次) ...

Core Viewpoint - The National Drug Centralized Procurement Office has announced the new centralized procurement document, emphasizing principles of clinical stability, quality assurance, prevention of collusion, and reduction of competition pressure in the pharmaceutical industry [1][3]. Summary by Sections Centralized Procurement Announcement - The announcement requires participating drugs to obtain valid domestic registration by September 28 and complete information submission on the National Medical Insurance Service Platform, with the bidding ceremony scheduled for October 21, 2025 [1]. Changes in Procurement Rules - The new procurement rules introduce a "benchmark price" for the same drug category, set at 50% of the average unit comparable price of validly declared companies and the higher value of the lowest unit comparable price. Companies can qualify for selection if their bid is below 1.8 times the benchmark price, a shift from the previous model that focused solely on the lowest price [3]. Participation and Reporting - A total of 46,359 medical institutions participated in the reporting, with 77% reporting by brand name and 23% by generic name. The drug list remains unchanged with 55 varieties, but mainstream specifications and prices have been noted [3]. Sodium Bicarbonate Injection Reporting - The total reported quantity of sodium bicarbonate injection across 31 provinces reached 71.5665 million units, with unspecified brands accounting for 47.45% of the total [5][9]. Manufacturer Performance - Among the specified brands, six manufacturers reported over 1 million units, with Shijiazhuang Fourth Pharmaceutical Company leading at 9.6542 million units, followed by Hebei Tiancai Pharmaceutical Co., Ltd. at 5.6166 million units [7][9]. Regional Preferences - Regional preferences for manufacturers are evident, with Yunnan showing a strong preference for Hebei Tiancai Pharmaceutical, while Shijiazhuang Fourth Pharmaceutical has a balanced national coverage [9][10]. Market Dynamics Ahead of Bidding - As the bidding date approaches, the market dynamics for sodium bicarbonate injection are expected to shift, influenced by brand preferences and the flow of unspecified brands, with companies that possess capacity, quality, and clinical recognition likely to emerge as winners in this round of procurement [10].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Anta Sports, conducted share buybacks on September 23, 2025, with Tencent leading in terms of buyback amount and quantity [1][2]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 867,000 shares for a total of 550 million [2]. - Anta Sports (02020) repurchased 2.12 million shares for a total of 200 million [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for a total of 23.57 million [2]. - China Petroleum & Chemical Corporation (00386) repurchased 5.51 million shares for a total of 22.44 million [2]. - Stone Four Pharmaceutical Group (02005) repurchased 5 million shares for a total of 14.67 million [2]. Group 2: Cumulative Buyback Data - Tencent's cumulative buyback for the year reached 61.59 million shares, accounting for 0.670% of its total share capital [2]. - Anta Sports' cumulative buyback for the year reached 4.24 million shares, accounting for 0.151% of its total share capital [2]. - China Hongqiao Group (01378) had a cumulative buyback of 15.2 million shares, accounting for 1.620% of its total share capital [2]. - Coolpad Group (02369) had a significant cumulative buyback of 27.25 million shares, accounting for 6.653% of its total share capital [2].